Archive Site Provided for Historical Purposes
Sponsored by the U.S. Department of Energy Human Genome Program
Human Genome News, January 1998; 9:(1-2)
Lawrence Livermore National Laboratory (LLNL) Human Genome Center and Onyx Pharmaceuticals, Inc., recently signed an agreement to collaborate in developing automated, high-throughput methods for generating proteins from gene sequences. To help identify and characterize new therapeutic targets for Onyx’s current drug-screening programs, research will focus on genes known to play a causative role in cancers. Joanna Albala of LLNL and Robin Clark and Anthony Davies of Onyx are principal investigators in the collaboration.
LLNL brings to the collaboration the Integrated Molecular Analysis of Gene Expression (called I.M.A.G.E.) collection of arrayed cDNA libraries, along with the expertise and infrastructure for miniaturizing and automating biological sample handling. Onyx has developed expertise and reagents for expressing proteins using the baculovirus expression system and for purifying a wide variety of human proteins using epitope tags. Investigators expect the new system to reduce drug-development time by providing a ready source of proteins for assay development and drug screening.
The 2-year collaboration is the first at LLNL to be funded under the Biotechnology Strategic Targets for Alliances in Research (BioSTAR) project. BioSTAR provides for university matching of private-sector funding for biotechnology research.
The electronic form of the newsletter may be cited in the following style:
Human Genome Program, U.S. Department of Energy, Human Genome News (v9n1).
The Human Genome Project (HGP) was an international 13-year effort, 1990 to 2003. Primary goals were to discover the complete set of human genes and make them accessible for further biological study, and determine the complete sequence of DNA bases in the human genome. See Timeline for more HGP history.